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Hepatocellular carcinoma (HCC) is the third leading cause of cancer-related death worldwide. This cancer develops mainly in
cirrhotic patients. The cirrhotic liver is considered to be a preneoplastic organ, suggesting the rationale for cancer prevention.
PPARγ is a nuclear transcription factor whose activation leads to interaction in the metabolism of lipids, insulin sensitization
of peripheral cells, anti-inﬂammatory action. It can also induce diﬀerentiation and inhibits proliferation of cancer cells. Until
now, data using PPARγ ligands in HCC have demonstrated mainly in in vitro models that its activation could be due to an
antiproliferative eﬀect. PPARγ ligand administration has also been associated with a diminution of liver ﬁbrosis in animal models,
and potentially also on tumoral cell death. Soma data show that the favorable eﬀect of natural and synthetized PPARγ agonists
couldalsobeindependentofPPARγ activation.Furthermore,insomesituations,PPARγ antagonistshavealsoananticancereﬀect.
Therefore, we can conclude that the link between activation of the PPARγ pathway and an anticancer activity is suggested but until
now not ﬁrmly established in HCC.
Copyright © 2008 I. Borbath and Y. Horsmans.ThisisanopenaccessarticledistributedundertheCreativeCommonsAttribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1. INTRODUCTION
Hepatocellular carcinoma (HCC) is the third leading cause
of cancer-related death worldwide [1]. Its prognosis is poor,
with up to 40% of patients diagnosed at an advanced
stage, when only palliative treatments can be oﬀered. Most
patients that develop HCC have cirrhosis, considered as a
preneoplasticorgan.Strategiestopreventthedevelopmentof
HCC have been implemented, by preventing the appearance
of cirrhosis (e.g., HBV vaccination and treatment) [2] or the
reappearance of HCC in cirrhotic patients (e.g., interferon in
HCV-related cirrhotic patients) [3].
PPARγ is a nuclear transcription factor, member of the
nuclear hormone receptor superfamily, being activated by
bindingitsligand,thenheterodimerizingwiththeRetinoidX
receptor,toﬁnallybindwithspeciﬁcresponseelementsinthe
nucleus, called peroxisome proliferating response elements.
Activation of PPARγ by agonists such as thiazolidinediones
(TZDs) has been shown to have anticancer eﬀectin vitroand
in vivo in many cancer types [4]. However, as emphasized
by articles in this special issue of PPAR research, in some
situations, like in colon cancer models, PPARγ agonists can
have tumor promoting eﬀects [5].
Eﬀect of PPARγ agonists on HCC has been studied in
the last years both in cell cultures and in animal models.
Here, we summarize the main ﬁndings of these works and
attempt to deﬁne the role of PPARγ and its modulation in
HCC.
2. EXPRESSION OF PPARγ IN RODENT
AND HUMAN LIVER
PPARγ RNA and protein expression has been demonstrated
in vitro in several cell lines, including Hep3B, HepG2, Huh7,
and others [6–11]. Its expression was generally higher than
positive control used but variable among cell lines, with
mRNA levels not necessarily correlating protein expression.
In human HCC, reports from 3 papers show conﬂicting
results: in the ﬁrst paper, PPARγ protein expression was
assessed by western-blot (WB) in 5 cirrhotic patients and
showed no diﬀerence between HCC and nontumoral cir-
rhotic liver [12]. The second paper showed a constant over-
expression of PPARγ p r o t e i ni n2 0H C C sa n dn oe x p r e s s i o n
in surrounding liver, assessed by immunohistochemistry
(IHC). In this paper, no information was given regarding the
presence of cirrhosis [13]. Finally, a recent report, analyzing2 PPAR Research
mRNA and protein expression (by WB) in 20 patients, with
cirrhosis (n = 12) and chronic hepatitis (n = 8), showed a
statistically signiﬁcant decrease in PPARγ expression in HCC
comparedtoadjacentliver[14].Furthermore,PPARγ mRNA
w a sl e s se x p r e s s e di np o o r l yd i ﬀerentiated HCC compared
to well-diﬀerentiated ones. The latter [2] results, using 2
diﬀerent methods (IHC versus WB) in diﬀerent populations,
can therefore not be compared, and certainly other analyses
willbeneededbeforewecandrawanyconclusionsonPPARγ
expression in HCC and cirrhosis compared to normal liver,
where it is known to be low [15].
3. EFFECT OF PPARγ AGONISTS ON
CELL PROLIFERATION
The eﬀect of the natural PPARγ agonist 15-deoxy-Δ12,14-
prostaglandin J2, and the synthetic agonists thiazolidine-
diones has been tested in many human HCC cell cultures
[6, 7, 9, 11, 12, 14, 16, 17]. Overall, cell growth was inhibited
at variable concentrations. Troglitazone, the most studied
TZD, was shown to inhibit cell growth already at 5–10μMol
concentrations, although some contradictory reports have
been published [10]. Pioglitazone and ciglitazone, the other
main TZDs tested, were less active, with concentrations from
50 to 100μMol needed to have signiﬁcant growth inhibitory
eﬀect. The antiproliferative eﬀect was shown to be due to
a cell cycle arrest, with cells accumulating at the G1 phase.
Koga et al. have performed the most thorough mechanistic
investigations in the ﬁeld [7, 12]. Using Troglitazone at
ad o s eo f5 0 μMol, they could show on several cell lines
that the inhibitory eﬀect on cell cycle was linked to an
increase in the mRNA and protein expression of the Cyclin-
dependent kinase inhibitor (Cki) p21waf1/cip1 and also an
increase in protein expression only of p27kip1, another CKi.
These proteins were shown to bind to the Cyclin-dependent
kinase CDK2, thus inhibiting its activation. Because the
intracellular concentration of p27kip1 is tightly regulated by
its degradation through the ubiquitin-proteasome pathway,
the authors have analyzed and could show that indeed,
troglitazone had an inhibitory eﬀect on p27kip1 degradation
via inhibition of Skp2, an F-box protein of ubiquitin-ligase
complex. These results were reproduced by others [11, 14,
18].
In vivo, four papers showed an inhibition of the devel-
opment of preneoplastic and neoplastic liver nodules by
PPARγ agonists. Kawaguchi et al. [19], using pioglitazone
in male Wistar rats fed with a choline-deﬁcient L-amino
acid deﬁned diet, which is an animal model of nonalcoholic
steatohepatitis (NASH) model, showed that pioglitazone, at
a concentration of 0.01%wt/wt, inhibited the formation of
GSTp positive foci by a factor 2. GSTp, the placental form of
Glutathione S-transferase, is an early marker of malignant
transformation, widely used in carcinogenic models [20].
Guo et al. [21], using three TZDs, namely, troglitazone,
rosiglitazone, and pioglitazone, in male Wistar rats showed
that all could suppress the formation of GSTp foci that
were induced by the strong mutagen diethylnitrosamine
(DEN). In a longer experiment aiming at tumor formation,
they found that pioglitazone at a 200ppm concentration,
equivalent to 0.05%wt/wt, prevented the appearance of
macroscopic tumors. However, in this paper, no histologic
proof of hepatocellular carcinoma was demonstrated, and
the quantitation of tumors is subject to criticism, with a
“stereomicroscopical” method used that is not described.
We recently published our results [22], using pioglitazone
at a dose of 0.01%wt/wt, in a carcinogenic 2-stage rat
model, using DEN and acetylaminoﬂuorene. We could show
that given early in the carcinogenic process, pioglitazone
inhibited the formation of preneoplastic foci to 50% of
the control group. This was accompanied by a signiﬁcant
decrease of proliferation in the transformed foci, and an
overexpression of the CKi p27kip1 in the pioglitazone-treated
group compared to control, thus reproducing some of the
results obtained in vitro. Finally, Yu et al. published their
results on the eﬀect of troglitazone, in vitro and in vivo in
a nude mice model, injected subcutaneously with the human
Huh7 HCC cell line [14]. They could show quite convinc-
ingly that troglitazone, at the 200ppm concentration, either
inhibited the appearance of HCC, or decreased the growth
of existing ones. The authors demonstrated that troglitazone
induced a decrease in proliferation, assessed by PCNA, an
increase in p27kip1 and a decrease of COX-2 expression in
tumors compared to controls.
It is important to mention that none of these studies,
using TZDs, has clearly demonstrated the antiproliferative
eﬀect of these drugs to be due to activation of PPARγ path-
way. In other cancer types, authors have demonstrated that
troglitazone and ciglitazone could inhibit cell proliferation
in PPARγ−/− cell lines, by inhibition of translation initiation
[23].
4. ROLE OF PPARγ IN THE PROGRESSION OF
LIVER FIBROSIS
An important paper published in 2002 by Galli et al. [24]
demonstrated that, given early, TZDs could signiﬁcantly
reduce the development of liver ﬁbrosis induced in rats,
either by chronic administration of dimethylnitrosamine,
carbon tetrachloride, or bile duct ligation. The authors
could show that this antiﬁbrotic eﬀect was driven through
aP P A R γ-dependant decreased activation of hepatic stellate
cells. These early results showing the importance of PPARγ
activation in the pathogenesis of ﬁbrosis were conﬁrmed by
others [25, 26]. Though, we could show that the protective
eﬀect was very dependant on the rodent type [27] and the
severity of ﬁbrosis at the time of initiation of treatment [28].
These data are thus to be interpreted with caution before
going to clinical application. In humans, one randomised
double-blind placebo-controlled study assessed the eﬀect of
pioglitazone versus placebo in patients with NASH [29].
One of the aims of the study was to assess ﬁbrosis on liver
biopsy before and after 6 months of a calorie-restricted
diet with or without pioglitazone. The study failed to
show diﬀerences in terms of ﬁbrosis regression, assessed by
histology, between groups (P = 0.08), although patients
in the pioglitazone group showed signiﬁcantly less ﬁbrosis
after the 6-month regimen compared to before treatment
(P = 0.002).I. Borbath and Y. Horsmans 3
5. PPARγ MODULATION IN ASSOCIATION
WITH CELL DEATH
T h er o l eo fP P A R γ in apoptosis and anoikis is less clear.
Several in vitro works report induction of apoptosis in
HCC cell lines, constantly by troglitazone and not by others
TZDs [9, 14, 30–32]. The main apoptotic mechanisms
remain poorly understood, although some publications
report an eﬀect of troglitazone on the bax/bcl-2 balance
[32], suggesting a role for the mitochondrial pathway. In
another work, authors have analyzed the eﬀect of the
natural PPARγ agonist 15-deoxy-Δ12,14-prostaglandin J2
(15D-JG2) on apoptosis of SK-Hep1 and hepG2 cells. They
indeed showed that given at a dose of 50μMol, 15D-JG2
could induce apoptosis by caspase 3 activation. Using PPARγ
antisense oligodeoxynucleotides, they demonstrated that
apoptosis was induced independently of PPARγ expression.
They also showed that 15d-PGJ2 inhibited NF-kB activation
induced by TNFα when PPARγ was normally expressed or
downregulated.
6. IS THERE A ROLE FOR PPARγ
INHIBITION IN CANCER?
Although, as discussed earlier in the text, the vast majority
of available data deals with PPARγ agonists, some authors
analyzedtheeﬀectofPPARγ inhibitorsoncancercellgrowth.
One publication reported the eﬀect of PPARγ inhibitors
on cell adhesion and anoikis [13]. On the contrary to the
paper by Yu et al. [14], authors found overexpression of
PPARγ in human HCC. They could show that these PPARγ
inhibitors increased loss of adherence in vitrofollowed by
caspase-dependent apoptosis, a ﬁnding reproduced using
PPARγ siRNAs, reﬂecting the speciﬁcity of the PPARγ-
dependent activation driving cell death. They also showed
that inhibitors were at least 5-fold more potent in reducing
cell number than troglitazone and rosiglitazone. Another
study evaluated the eﬀect of PPARγ agonists and antagonists
on cell growth, migration, and invasion in four diﬀerent
HCC cell lines [33]. Authors could show that antagonists
inhibited cell growth and migration more eﬃciently than
PPAR agonists. They suggest that this eﬀect could be due
to Vimentin cleavage, thus interacting negatively with the
cellular cytoskeleton.
7. CONCLUSION
SeveralinvitroandinvivopaperssuggestaroleofthePPARγ
pathway in the prevention and treatment of HCC. PPARγ
mRNA and protein expression are constantly found in cell
lines. In normal liver, it is known to be expressed at low
levels, ten times less than in adipose tissue. We do not know
its actual level of expression, neither in cirrhotic nontumoral
liver, nor in HCC, with conﬂicting results reported. Thiazo-
lidinediones, which are active and speciﬁc PPARγ agonists,
have shown antitumoral activity in cell lines and in animal
models. This anticancer activity is due to inhibition of cell
proliferation, by interfering with important cell cycle cyclins
and cyclin-dependent kinase inhibitors, such as p27kip1,b u t
also by a proapoptotic action. The link between activation
of the PPARγ pathway and the anticancer activity of TZDs
is, however, not established. Finally, PPARγ antagonists have
shown antitumor activity, by diﬀerent mechanisms, mainly
involving loss of cell adherence, migration, and invasion.
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